Stryker (SYK) Q3 2026 Earnings Call Transcript
Stryker (SYK) reported Q3 2026 earnings, with organic sales growth of 7.7% and adjusted EPS of $3.52. The company faced delays in new product sales due to a cyber incident and SAP implementation but remains confident in long-term growth. Stryker updated its guidance, expecting similar Q4 growth. Recent acquisitions include ZuriMED and an investment in CMR Surgical. Vascular business showed sequential improvement, and the company anticipates commercializing AVS' IVL platform in 2027.
How this was made
The 30-second read
Why it matters
The call provides decision-relevant updates: updated organic growth expectations for Q4, full-year effective tax rate guidance, and a supply normalization path for Peripheral Vascular, alongside M&A and strategic investment announcements.
Market read
Traders can update near-term expectations for Stryker’s Q4 organic growth and EPS trajectory based on margin expansion and supply normalization, while monitoring execution risks in new product sales.
What to watch
Vascular outlook depends on continued normalization of inventory and availability through year-end, plus timing of AVS IVL platform commercialization and PEERLESS II FlowTriever data in 2027.
Background
This is a Q3 2026 earnings call transcript for Stryker, covering segment performance, margin drivers, supply disruption in Vascular, and updates on new product commercialization and pipeline data.
Ticker impact
Stryker reports Q3 results and updated full-year outlook, including organic sales growth, EPS, margin expansion, and supply normalization guidance.
Likely modest upward bias as investors weigh margin expansion and normalized inventory expectations against commercial execution delays.
The transcript includes specific Q3 performance metrics (organic sales, adjusted EPS, margins) plus an updated outlook and supply normalization through year-end, which are direct inputs to near-term valuation.
Market effects
Signals continued demand strength across MedSurg, Endoscopy, and Instruments, with ongoing execution risk around new product commercialization.
Highlights geographic growth leadership in Australia, Germany, Canada, and India, relevant for regional medtech demand expectations.
Reinforces broad-based procedure environment assumptions and elevated capital demand for surgical systems and enabling technologies.
Counterpoint
Despite margin expansion, the company is behind expectations on new product sales (Mako RPS and Triathlon Gold) and cites cyber incident and SAP implementation as execution headwinds.
Key entities
- companyStryker
Reports Q3 2026 results, updated outlook, and discusses supply normalization, margin expansion, and new product execution issues.
- acquired_companyZuriMED
Stryker completed acquisition to expand support in sports medicine and arthroplasty, including fiber locker technology.
- strategic_partnerCMR Surgical
Stryker announced a strategic investment and an exclusive U.S. sales agency agreement for the Versius platform.
